GEHC — GE HealthCare Technologies Inc.

GE HealthCare Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $5.1 billion, reflecting 2.9% organic growth year-over-year, at the high end of expectations.
• Adjusted EBIT Margin: 13.5%, down 150 basis points year-over-year.
• Adjusted EPS: $0.99, impacted by approximately $0.16 from tariffs.
• Free Cash Flow: $112 million, up $13 million year-over-year.
• Orders Growth: 1.1%, with a book-to-bill ratio of 1.07x and a record backlog of $21.8 billion, up $1.2 billion year-over-year.

2. Strategic Updates and Business Highlights

• Strong performance in pharmaceutical diagnostics, advanced visualization solutions, and imaging businesses, with double-digit growth in EMEA and Rest of World.
• Advances in Precision Care with regulatory clearances for the Photonova Spectra CT platform and multiple FDA clearances in MR technologies.
• Growth in radiopharmaceuticals, particularly Flyrcado, which saw an 80% increase in doses since late January.
• Acquisition of Intelerad completed, aimed at enhancing cloud capabilities and driving recurring revenue.
• Restructuring to form a new segment, Advanced Imaging Solutions (AIS), to streamline operations and enhance focus on innovation.

3. Forward Guidance and Outlook

• Maintaining organic sales growth guidance of 3% to 4% for 2026.
• Adjusted EBIT margin expected to be in the range of 15.4% to 15.7%, reflecting a slight year-over-year expansion.
• Adjusted EPS guidance reduced to $4.80 to $5.00 per share, indicating 5% to 9% growth year-over-year.
• Anticipating free cash flow of approximately $1.6 billion for 2026.

4. Bad News, Challenges, or Points of Concern

• Profit performance was negatively impacted by a supplier recall in the PDx business and rising material costs, particularly memory chips and oil, leading to a $250 million inflation impact.
• Adjusted EBIT margin decline attributed to tariff impacts and challenges in the Patient Care Solutions (PCS) segment, which saw an 8.1% revenue decline.
• Cautious outlook on China market performance, with expectations of year-over-year revenue decline, although some signs of stabilization were noted.
• Concerns about inflationary pressures and their potential impact on margins and profitability throughout the year.

5. Notable Q&A Insights

• Management expressed confidence in the ability to accelerate revenue in the second half of 2026, driven by strong order growth and new product introductions.
• The inflationary impact was discussed, with management indicating that the most significant effects would be felt in Q2 and Q3, with mitigation measures expected to take effect in the latter half of the year.
• The new AIS segment is expected to enhance growth by improving product development and customer engagement.
• On the competitive landscape, management noted no current impact from generic entrants in the pharmaceutical diagnostics market, emphasizing the importance of product breadth and supply chain resilience.
• The timeline for the new gadolinium-free MRI contrast agent suggests potential market introduction by 2029 if clinical trials proceed successfully.

This summary encapsulates the key aspects of GE HealthCare's Q1 2026 earnings call, highlighting both the positive developments and the challenges faced by the company.